Effect of small molecule vasopressin V1a and V2 receptor antagonists on brain edema formation and secondary brain damage following traumatic brain injury in mice

Journal of Neurotrauma

Volumn 32, Issue 4, 2015, Pages 221-227

  Krieg, Sandro M ^a   Sonanini, Sebastian ^a   Plesnila, Nikolaus ^a   Trabold, Raimund ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

arginine vasopressin; brain edema; CBF; traumatic brain injury

Indexed keywords

RELCOVAPTAN; SATAVAPTAN; VASOPRESSIN; VASOPRESSIN V1A RECEPTOR; VASOPRESSIN V2 RECEPTOR; INDOLE DERIVATIVE; MORPHOLINE DERIVATIVE; PYRROLIDINE DERIVATIVE; SPIRO COMPOUND; VASOPRESSIN RECEPTOR; VASOPRESSIN RECEPTOR ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN BLOOD FLOW; BRAIN CONTUSION; BRAIN DAMAGE; BRAIN EDEMA; BRAIN WATER; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG SELECTIVITY; INTRACRANIAL PRESSURE; MALE; MOUSE; NONHUMAN; TRAUMATIC BRAIN INJURY; VASCULAR ENDOTHELIUM; ANIMAL; BRAIN INJURY; C57BL MOUSE; DISEASE MODEL; DRUG EFFECTS; METABOLISM; PATHOLOGY;

ANIMALS; ANTIDIURETIC HORMONE RECEPTOR ANTAGONISTS; BRAIN EDEMA; BRAIN INJURIES; DISEASE MODELS, ANIMAL; INDOLES; MALE; MICE; MICE, INBRED C57BL; MORPHOLINES; PYRROLIDINES; RECEPTORS, VASOPRESSIN; SPIRO COMPOUNDS;

EID: 84923276178     PISSN: 08977151     EISSN: 15579042     Source Type: Journal    
DOI: 10.1089/neu.2013.3274     Document Type: Article

References (47)

1. Corrigan, J.D., Selassie, A.W., and Orman, J.A. (2010). The epidemiology of traumatic brain injury. J. Head Trauma Rehabil. 25, 72-80.
2. Giacoppo, S., Bramanti, P., Barresi, M., Celi, D., Foti Cuzzola, V, Palella, E., and Marino, S. (2012). Predictive biomarkers of recovery in traumatic brain injury. Neurocrit. Care 16, 470-477.
3. Pearl, G.S. (1998). Traumatic neuropathology. Clin. Lab. Med. 18, 39-64.
4. Borgens, R.B., and Liu-Snyder, P. (2012). Understanding secondary injury. Q. Rev. Biol. 87, 89-127.
5. Kermer, P., Klocker, N., and Bahr, M. (1999). Neuronal death after brain injury. Models, mechanisms, and therapeutic strategies in vivo. Cell Tissue Res. 298, 383-395.
6. Buijs, R.M. (1980). Immunocytochemical demonstration of vasopressin and oxytocin in the rat brain by light and electron microscopy. J. Histochem. Cytochem. 28, 357-360.
7. Riphagen, C.L. and Pittman, Q.J. (1986). Arginine vasopressin as a central neurotransmitter. Fed. Proc. 45, 2318-2322.
8. Faraci, F.M., Mayhan, W.G., and Heistad, D.D. (1990). Effect of vasopressin on production of cerebrospinal fluid: possible role of vasopressin (V1)-receptors. Am. J. Physiol. 258, R94-R98.
9. Faraci, F.M., Mayhan, W.G., Schmid, P.G., and Heistad, D.D. (1988). Effects of arginine vasopressin on cerebral microvascular pressure. Am. J. Physiol. 255, H70-H76.
10. Fernandez, N., Martinez, M.A., Garcia-Villalon, A.L., Monge, L., and Dieguez, G. (2001). Cerebral vasoconstriction produced by vasopressin in conscious goats: role of vasopressin V(1) and V(2) receptors and nitric oxide. Br. J. Pharmacol. 132, 1837-1844.
11. Raichle, M.E., and Grubb, R.L., Jr. (1978). Regulation of brain water permeability by centrally-released vasopressin. Brain Res. 143, 191-194.
12. Rosenberg, G.A., Kyner, W.T., Fenstermacher, J.D., and Patlak, C.S. (1986). Effect of vasopressin on ependymal and capillary permeability to tritiated water in cat. Am. J. Physiol. 251, F485-F489.
13. Niermann, H., miry-Moghaddam, M., Holthoff, K., Witte, O.W., and Ottersen, O.P. (2001). A novel role of vasopressin in the brain: modulation of activity-dependent water flux in the neocortex. J. Neurosci. 21, 3045-3051.
14. Del Bigio, M.R., and Fedoroff, S. (1990). Swelling of astroglia in vitro and the effect of arginine vasopressin and atrial natriuretic peptide. Acta Neurochir. Suppl (Wien) 51, 14-16.
15. Hertz, L., Chen, Y., and Spatz, M. (2000). Effects of arginine vasopressin on water space in astrocytes and in whole brain. Am. J. Physiol. Endocrinol. Metab. 278, E1175-E1176.
16. Lolait, S.J., OCarroll, A.M., Mahan, L.C., Felder, C.C., Button, D.C., Young, W.S., III, Mezey, E., and Brownstein, M.J. (1995). Extrapituitary expression of the rat V1b vasopressin receptor gene. Proc. Natl. Acad. Sci. U. S. A 92, 6783-6787.
17. Kato, Y., Igarashi, N., Hirasawa, A., Tsujimoto, G., and Kobayashi, M. (1995). Distribution and developmental changes in vasopressin V2 receptor mRNA in rat brain. Differentiation 59, 163-169.
18. Ostrowski, N.L., Lolait, S.J., and Young, W.S., III (1994). Cellular localization of vasopressin V1a receptor messenger ribonucleic acid in adult male rat brain, pineal, and brain vasculature. Endocrinology 135, 1511-1528.
19. Brinton, R.E., Gee, K.W., Wamsley, J.K., Davis, T.P., and Yamamura, H.I. (1984). Regional distribution of putative vasopressin receptors in rat brain and pituitary by quantitative autoradiography. Proc. Natl. Acad. Sci. U. S. A 81, 7248-7252.
20. Hockel, K., Scholler, K., Trabold, R., Nussberger, J., and Plesnila, N. (2012). Vasopressin V(1a) receptors mediate posthemorrhagic systemic hypertension thereby determining rebleeding rate and outcome after experimental subarachnoid hemorrhage. Stroke 43, 227-232.
21. Trabold, R., Krieg, S., Scholler, K., and Plesnila, N. (2008). Role of vasopressin V(1a) and V2 receptors for the development of secondary brain damage after traumatic brain injury in mice. J. Neurotrauma 25, 1459-1465.
22. Vakili, A., Kataoka, H., and Plesnila, N. (2005). Role of arginine vasopressin V1 and V2 receptors for brain damage after transient focal cerebral ischemia. J. Cereb. Blood Flow Metab. 25, 1012-1019.
23. Rosenberg, G.A., Scremin, O., Estrada, E., and Kyner, W.T. (1992). Arginine vasopressin V1-antagonist and atrial natriuretic peptide reduce hemorrhagic brain edema in rats. Stroke 23, 1767-1774.
24. Xu, M., Su, W., Huang, W.D., Lu, Y.Q., Xu, Q.P., and Chen, Z.J. (2007). Effect of AVP on brain edema following traumatic brain injury. Chin. J. Traumatol. 10, 90-93.
25. Mather, H.M., Ang, V., and Jenkins, J.S. (1981). Vasopressin in plasma and CSF of patients with subarachnoid haemorrhage. J. Neurol. Neurosurg. Psychiatry 44, 216-219.
26. Joynt, R.J., Feibel, J.H., and Sladek, C.M. (1981). Antidiuretic hormone levels in stroke patients. Ann. Neurol. 9, 182-184.
27. Serradeil-Le Gal, C., Wagnon, J., Garcia, C., Lacour, C., Guiraudou, P., Christophe, B., Villanova, G., Nisato, D., Maffrand, J.P., Le Fur G., et al. (1993). Biochemical and pharmacological properties of SR 49059, a new, potent, nonpeptide antagonist of rat and human vasopressin V1a receptors. J. Clin. Invest. 92, 224-231.
28. Serradeil-Le Gal, C., Lacour, C., Valette, G., Garcia, G., Foulon, L., Galindo, G., Bankir, L., Pouzet, B., Guillon, G., Barberis, C., Chicot, D., Jard, S., Vilain, P., Garcia, C., Marty, E., Raufaste, D., Brossard, G., Nisato, D., Maffrand, J.P., and Le Fur, G. (1996). Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist. J. Clin. Invest. 98, 2729-2738.
29. Thal, S.C., and Plesnila, N. (2007). Non-invasive intraoperative monitoring of blood pressure and arterial pCO2 during surgical anesthesia in mice. J. Neurosci. Methods 159, 261-267.
30. von Baumgarten L., Trabold, R., Thal, S., Back, T., and Plesnila, N. (2008). Role of cortical spreading depressions for secondary brain damage after traumatic brain injury in mice. J. Cereb. Blood Flow Metab. 28, 1353-1360.
31. Zweckberger, K., Stoffel, M., Baethmann, A., and Plesnila, N. (2003). Effect of decompression craniotomy on increase of contusion volume and functional outcome after controlled cortical impact in mice. J. Neurotrauma 20, 1307-1314.
32. Zweckberger, K., Eros, C., Zimmermann, R., Kim, S.W., Engel, D., and Plesnila, N. (2006). Effect of early and delayed decompressive craniectomy on secondary brain damage after controlled cortical impact in mice. J. Neurotrauma 23, 1083-1093.
33. Brouard, R., Laporte, V., Serradeil Le Gal C., Pignol, R., Jang, H., Donat, F., Lockwood, G., Fournie, D., and Dreux, F. (1998). Safety, tolerability, and pharmacokinetics of SR 49059, a V1a vasopressin receptor antagonist, after repeated oral administration in healthy volunteers. Adv. Exp. Med. Biol. 449, 455-465.
34. Serradeil-Le, G.C., Wagnon, J., Simiand, J., Griebel, G., Lacour, C., Guillon, G., Barberis, C., Brossard, G., Soubrie, P., Nisato, D., Pascal, M., Pruss, R., Scatton, B., Maffrand, J.P., and Le, F.G. (2002). Characterization of (2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N, N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a selective and orally active vasopressin V1b receptor antagonist. J. Pharmacol. Exp. Ther. 300, 1122-1130.
35. Trabold, R., Schueler, O.G., Eriskat, J., Plesnila, N., Baethmann, A.J., and Back, T. (2006). Arterial hypotension triggers perifocal depolarizations and aggravates secondary damage in focal brain injury. Brain Res. 1071, 237-244.
36. Doczi, T., Laszlo, F.A., Szerdahelyi, P., and Joo, F. (1984). Involvement of vasopressin in brain edema formation: further evidence obtained from the Brattleboro diabetes insipidus rat with experimental subarachnoid hemorrhage. Neurosurgery 14, 436-441.
37. Manaenko, A., Fathali, N., Khatibi, N.H., Lekic, T., Hasegawa, Y., Martin, R., Tang, J., and Zhang, J.H. (2011). Arginine-vasopressin V1a receptor inhibition improves neurologic outcomes following an intracerebral hemorrhagic brain injury. Neurochem. Int. 58, 542-548.
38. Liu, X.F., Shi, Y.M., and Lin, B.C. (1991). Mechanism of action of arginine vasopressin on acute ischemic brain edema. Chin. Med. J. (Engl.) 104, 480-483.
39. Dickinson, L.D., and Betz, A.L. (1992). Attenuated development of ischemic brain edema in vasopressin-deficient rats. J. Cereb. Blood Flow Metab. 12, 681-690.
40. Armstead, W.M. (2001). Vasopressin induced cyclooxygenase dependent superoxide generation contributes to K( + ) channel function impairment after brain injury. Brain Res. 910, 19-28.
41. Pascale, C.L., Szmydynger-Chodobska, J., Sarri, J.E., and Chodobski, A. (2006). Traumatic brain injury results in a concomitant increase in neocortical expression of vasopressin and its V(1a) receptor. J. Physiol. Pharmacol. 57, Suppl 11, 161-167.
42. Barreca, T., Gandolfo, C., Corsini, G., Del, S.M., Cataldi, A., Rolandi, E., and Franceschini, R. (2001). Evaluation of the secretory pattern of plasma arginine vasopressin in stroke patients. Cerebrovasc. Dis. 11, 113-118.
43. Huang, W.D., Pan, J., Xu, M., Su, W., Lu, Y.Q., Chen, Z.J., Jiang, T.Y., and Yang, Y.M. (2008). Changes and effects of plasma arginine vasopressin in traumatic brain injury. J. Endocrinol. Invest 31, 996-1000.
44. Nagao, S., Kagawa, M., Bemana, I., Kuniyoshi, T., Ogawa, T., Honma, Y., and Kuyama, H. (1994). Treatment of vasogenic brain edema with arginine vasopressin receptor antagonist-an experimental study. Acta Neurochir. Suppl. (Wien) 60, 502-504.
45. Doczi, T., Szerdahelyi, P., Gulya, K., and Kiss, J. (1982). Brain water accumulation after the central administration of vasopressin. Neurosurgery 11, 402-407.
46. Chen, Y., McNeill, J.R., Hajek, I., and Hertz, L. (1992). Effect of vasopressin on brain swelling at the cellular level: do astrocytes exhibit a furosemide-vasopressin-sensitive mechanism for volume regulation? Can. J. Physiol. Pharmacol. 70, Suppl, S367-S373.
47. Bemana, I., and Nagao, S. (1999). Treatment of brain edema with a nonpeptide arginine vasopressin V1 receptor antagonist OPC-21268 in rats. Neurosurgery 44, 148-155.